"In regards to Arizona, we've partnered with two large clinics, which represent around 65,000 patients. Most of the patients are Type I diabetics, so it's a good fit for ALTuCELL where we can do our clinical trial work," explained Moscato,
//////
I’ve only read the press release version of the podcast. But I would be very surprised if the FDA would agree to this.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links